Brief: PolyPid Announces Recruitment Of First Patient In Revised Shield II Phase 3 Trial Evaluating D-Plex₁₀₀ For Prevention Of Abdominal Colorectal Surgical Site Infections
22/06/2023 12:36
June 22 (Reuters) - PolyPid Ltd PYPD.O :
* POLYPID ANNOUNCES RECRUITMENT OF FIRST PATIENT IN REVISED
SHIELD
II PHASE 3 TRIAL EVALUATING D-PLEX₁₀₀ FOR PREVENTION OF
ABDOMINAL COLORECTAL SURGICAL SITE INFECTIONS
* POLYPID LTD - TOP-LINE RESULTS EXPECTED IN MID-2024
* POLYPID LTD - ALSO INTENDS TO CONDUCT AN UNBLINDED INTERIM
ANALYSIS ONCE A TOTAL OF ABOUT 400 PATIENTS COMPLETE THEIR
30-DAY FOLLOW-UP
Source text for Eikon: ID:nGNX8jGjP4
Further company coverage: PYPD.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Polypid
See all newsPolyPid Ltd reports results for the quarter ended June 30 - Earnings Summary
PolyPid Ltd expected to post a loss of 38 cents a share - Earnings Preview
Brief: Polypid Announces FDA Acceptance Of NDA With Priority Review For D-Plex₁₀₀
PolyPid, Azurity sign surgical site infection drug deal
Brief: Polypid Initiates D-Plex₁₀₀ NDA Submission To The FDA